Johnson & Johnson Completes Initial Tender Offer for Cougar Bio...(ing assumptions prove inaccurate or unkn...)

Date:7/3/2009

ing assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include: general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Cougar Biotechnology, Inc. Johnson & Johnson has filed a tender offer statement with the SEC, and has mailed an offer to purchase, forms of letter of transmittal and related documents to Cougar Biotechnology shareholders. Cougar Biotechnology has filed with the SEC, and has mailed to Cougar Biotechnology shareholders, a solicitation/recommendation statement on Schedule 14D-9. These documents contain important information about the tender offer and shareholders of Cougar Biotechnology are urged to read them carefully when they are received.

These documents are available at no charge at the SEC's website at

SOURCE Johnson & Johnson Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
2. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
3. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
4. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
5. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
6. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
7. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
8. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
9. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
10. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
11. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research